Nebivolol Education Efforts Will Tout Performance In Hypertension Subgroups
Executive Summary
Forest has already started conducting postmarketing studies for its antihypertensive nebivolol - in advance of the product's approval - "to further highlight potential differences from existing beta blockers," according to Investor Relations VP Charles Triano
You may also be interested in...
Forest Hopes Efficacy In Blacks And Tolerability Will Set Bystolic Apart
With approval of Forest/Mylan's Bystolic (nebivolol) - the newest member of a crowded beta blocker class - the company is gearing up to launch with an experienced sales force, data to differentiate the drug, and a price in line with one of the most commonly used drugs in the class
Forest Hopes Efficacy In Blacks And Tolerability Will Set Bystolic Apart
With approval of Forest/Mylan's Bystolic (nebivolol) - the newest member of a crowded beta blocker class - the company is gearing up to launch with an experienced sales force, data to differentiate the drug, and a price in line with one of the most commonly used drugs in the class
Drug Reimbursement In Brief From Pharma Earnings Calls
Formulary access for Lipitor: "Our access remains in the range of 65 to 70 [percent] at tier 2 across commercial and Medicare lives," Pfizer Worldwide Pharmaceutical Operations President Ian Read commented during the firm's third quarter earnings call Oct. 18. Noting that U.S. prescriptions for the cholesterol reducer were down about 13 percent compared to 2006, he pointed out that losses from patient switches to generics have "stabilized" and the product's new patient volume is "fluctuating at around a 20 percent share." Lipitor's third quarter revenues declined 3 percent to $3.2 billion versus the comparable 2006 quarter...